JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended ...

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

Hospitalizations due to RSV cases in infants are reduced by up to 43% following the introduction of new maternal vaccines.

A groundbreaking universal snake antivenom, derived from rare human antibodies, offers hope against deadly bites worldwide.

A research team at the Terasaki Institute, led by Dr. Vadim Jucaud in collaboration with Dr. Jing Yong Ye from the University ...

Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility ...

Rabies is one of the deadliest infectious diseases, but it is also preventable when treated quickly after an animal bite. A ...

When Laura Ehrlich gave birth to her first child in 2020, the COVID-causing virus wasn’t the only threat facing her son. Born ...

A research team at the Terasaki Institute, led by Dr. Vadim Jucaud in collaboration with Dr. Jing Yong Ye from the University ...

Jade Biosciences (JBIO) unveiled JADE201, its investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating ...

The antibody contract manufacturing market is poised for growth, driven by increasing outsourcing due to cost efficiency and ...

A research team at the Terasaki Institute, led by Dr. Vadim Jucaud in collaboration with Dr. Jing Yong Ye from the University of Texas San Antonio, has developed a new microfluidic-based biosensing ...